Compounds > n(1),n(14)-bis(ethyl)homospermine
Page last updated: 2024-12-06

n(1),n(14)-bis(ethyl)homospermine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(1),N(14)-bis(ethyl)homospermine: structure given in first source; depletes polyamines and inhibits the growth of tumor cells in tissue culture [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60702
CHEMBL ID77101
SCHEMBL ID426504
MeSH IDM0162658

Synonyms (33)

Synonym
CHEMBL77101
dehspm
n(1),n(14)-bis(ethyl)homospermine
n,n'-bis(4-(ethylamino)butyl)-1,4-butanediamine
diethylhomospermine
be-4-4-4
drg-0203
1,14-bis(ethylamino)-5,10-diazatetradecane
n1 n14-bis(ethyl)norspermine
n(1),n(14)-diethylhomospermine
n(sup 1),n(sup 14)-diethylhomospermine
behspm
n(sup 1),n(sup 14)-bis(ethyl)homospermine
1,4-butanediamine, n,n'-bis(4-(ethylamino)butyl)-
n-ethyl-n'-[4-[4-(ethylamino)butylamino]butyl]butane-1,4-diamine
dehsm
nsc741423
n1,n14-diethylhomospermine
n1,n14-bis(ethyl)homospermine
119422-08-1
nsc-741423
unii-8g6x94gnho
8g6x94gnho ,
nsc 741423
diethylhomospermine [who-dd]
SCHEMBL426504
dehop
DTXSID20152459
DB13011
n1,n1'-(butane-1,4-diyl)bis(n4-ethylbutane-1,4-diamine)
Q27270391
STARBLD0001916
AKOS040748250

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Thus, chronic DEHSPM dosing regimens in both dogs and mice may result in the accumulation of HSPM, which is retained by tissues for an extended period of time resulting in disruption of normal polyamine homeostasis in these tissues."( Metabolism and pharmacokinetics of N1,N14-diethylhomospermine.
Bergeron, RJ; Luchetta, G; Sninsky, CA; Weimar, WR; Wiegand, J, 1996)		0.29
" On the basis of subcutaneous dose-response data and toxicity profiles, two compounds, N(1),N(12)-diisopropylspermine and N(1),N(12)-diethylspermine, were taken forward into more complete evaluation."( Polyamine analogue antidiarrheals: a structure-activity study.
Algee, SE; Bergeron, RJ; Fannin, TL; McManis, JS; Slusher, MA; Smith, RE; Snyder, PS; Weimar, WR; Wiegand, J, 2001)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (104)

Assay IDTitleYearJournalArticle
AID220837HSPM Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220838MESPM/MEHSPH Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID150568Inhibition of ornithine decarboxylase (ODC) activity1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Antiproliferative properties of polyamine analogues: a structure-activity study.
AID97360Compound level in L1210 cells after 48 hours of incubation at initial concentration of 10 uM is expressed as nmol/10e6 cells1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Antiproliferative properties of polyamine analogues: a structure-activity study.
AID94587Competitive inhibition of [3H]SPD (spermidine) transport in JURKAT cells1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID122743Effect of Chronic compound treatment on polyamine homeostasis in mouse kidney(drug [N+]) at total dose of 90 mg/kg1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Metabolically programmed polyamine analogue antidiarrheals.
AID96578Ki was estimated by competitive inhibition of [3H]SPD transport by L1210 cells2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID220822Distribution in kidney was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-36 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID96873Spermidine(SPD) levels in L1210 cells after 48 hr of treatment with the compound at the dose of 0.75 uM2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID218614Spermine Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220831Distribution in liver was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-27 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID122745Effect of Chronic compound treatment on polyamine homeostasis in mouse kidney (native[N+]) at total dose of 90 mg/kg1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Metabolically programmed polyamine analogue antidiarrheals.
AID27456Half-life period in liver tissues2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID122757Effect of Chronic compound treatment on polyamine homeostasis in mouse liver(total[N+]) at total dose of 90 mg/kg1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Metabolically programmed polyamine analogue antidiarrheals.
AID220710Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID26614Acid base constant value for N1 atom1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study.
AID26881Acid base constant value for N4 atom1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study.
AID203886Inhibition of spermidine/spermine N1-Acetyltransferase (SSAT) activity1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Antiproliferative properties of polyamine analogues: a structure-activity study.
AID220835HSPM Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID26863Acid base constant value for N3 atom1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study.
AID94591effect of compound on polyamine biosynthetic enzymes in JURKAT cells using ODC assay1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID220714Distribution in kidney was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID94598% of spermine (SPM) in JURKAT cells after 144 hr at 2 uM concentration1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID96872Spermidine(SPD) levels in L1210 cells after 48 hr of treatment with the compound at the dose of 0.15 uM2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID96740Putrescine(PUT) levels in L1210 cells after 48 hr of treatment with the compound at the dose of 0.75 uM2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID96888Spermine(SPM) levels in L1210 cells after 48 hr of treatment with the compound at the dose of 10 uM2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID122754Effect of Chronic compound treatment on polyamine homeostasis in mouse liver (native[N+]) at total dose of 90 mg/kg1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Metabolically programmed polyamine analogue antidiarrheals.
AID220828Distribution in liver was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID199310Effect of compound on rat liver S-Adenosyl-methionine decarboxylase in L1210 cells2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID156180Inhibition of cell growth was determined in PC-3 cell line of human prostate tumor using MTT assay, on day 6 after treatment2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Conformationally restricted analogues of 1N,14N-bisethylhomospermine (BE-4-4-4): synthesis and growth inhibitory effects on human prostate cancer cells.
AID421190Antitumor activity against human MALME-3M cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Recent advances in the development of polyamine analogues as antitumor agents.
AID94590effect of compound on polyamine biosynthetic enzymes in JURKAT cells using AdoMetDC assay1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID96564Growth inhibitory activity of compound on L1210 cells after 96 hours1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Metabolically programmed polyamine analogue antidiarrheals.
AID220716Distribution in kidney was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-27 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220826Distribution in liver was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52.4 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID218625Spermine Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220823Distribution in kidney was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-36 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID122747Effect of Chronic compound treatment on polyamine homeostasis in mouse kidney (total[N+]) at total dose of 90 mg/kg1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Metabolically programmed polyamine analogue antidiarrheals.
AID100383Inhibition of cell growth was determined in LNCaP cell line of human prostate tumor using MTT assay, on day 6 after treatment2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Conformationally restricted analogues of 1N,14N-bisethylhomospermine (BE-4-4-4): synthesis and growth inhibitory effects on human prostate cancer cells.
AID55942Inhibition of cell growth was determined in DUPRO cell line of human prostate tumor using MTT assay, on day 6 after treatment2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Conformationally restricted analogues of 1N,14N-bisethylhomospermine (BE-4-4-4): synthesis and growth inhibitory effects on human prostate cancer cells.
AID218615Spermine Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID98379In vitro inhibition of L1210 growth after 48 hours.1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Antiproliferative properties of polyamine analogues: a structure-activity study.
AID199308Inhibition of S-Adenosyl-methionine decarboxylase (AdoMetDC) activity1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Antiproliferative properties of polyamine analogues: a structure-activity study.
AID220982Spermidine Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID98808% of putrescine (PUT) in L1210 cells after 48 hr at 10 uM concentration1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID97891In vitro inhibition of uptake [3H]-spermidine in L1210 (murine leukemia) cells.1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Metabolically programmed polyamine analogue antidiarrheals.
AID122753Effect of Chronic compound treatment on polyamine homeostasis in mouse liver (drug[N+]) at total dose of 90 mg/kg1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Metabolically programmed polyamine analogue antidiarrheals.
AID94594% of putrescine (PUT) in JURKAT cells after 144 h at 2 uM concentration1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID220834HSPM Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID151016Effect of compound on Ornithine decarboxylase (ODC) from mouse kidney in L1210 cells2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID96876Spermidine(SPD) levels in L1210 cells after 48 hr of treatment with the compound at the dose of 10 uM2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID220713Distribution in kidney was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220709Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID218624Spermine Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID98810% of spermidine (SPD) in L1210 cells after 48 hr at 10 uM concentration1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID98900Inhibitory activity against growth of L1210 cells.1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID220829Distribution in liver was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID96739Putrescine(PUT) levels in L1210 cells after 48 hr of treatment with the compound at the dose of 0.15 uM2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID203890Effect of compound on Spermidine/Spermine N'-Acetyltransferase(SSAT) in L1210 cells2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID220827Distribution in liver was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52.4 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID96563Growth inhibitory activity of compound on L1210 cells after 48 hours1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Metabolically programmed polyamine analogue antidiarrheals.
AID94592% of hypusine (Hpu) in JURKAT cells after 144 hr at 2 uM concentration1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID116878Acute toxicity was assessed after ip administration of a single dose of 325 mg/kg to a group of 5 female CD-1 mice1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Metabolically programmed polyamine analogue antidiarrheals.
AID98651effect of compound on polyamine biosynthetic enzymes in L1210 cells using AdoMetDC assay1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID220983Spermidine Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID97887Inhibition of radiolabeled spermidine uptake into L1210 cells in vitro.1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Antiproliferative properties of polyamine analogues: a structure-activity study.
AID220824Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID97890Activity of compound measured against L1210 cells1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID220832Distribution in liver was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-36 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220715Distribution in kidney was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-27 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220711Distribution in kidney was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52.4 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID94596% of spermidine (SPD) in JURKAT cells after 144 hr at 2 uM concentration1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID220848MESPM/MEHSPH Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220836HSPM Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID98320Growth uM after 96 hours2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID98812% of spermine (SPM) in L1210 cells after 48 hr at 10 uM concentration1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID220825Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID99115Compound was evaluated for its impact on spermidine levels after 48 hr at concentration 10 uM1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Antiproliferative properties of polyamine analogues: a structure-activity study.
AID218605Spermidine Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID44520The chronic toxicity was determined in female CD1 mice after (ip) administration2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220849MESPM/MEHSPH Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220712Distribution in kidney was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52.4 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID55812Inhibition of cell growth was determined in DU145 cell line of human prostate tumor using MTT assay, on day 6 after treatment2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Conformationally restricted analogues of 1N,14N-bisethylhomospermine (BE-4-4-4): synthesis and growth inhibitory effects on human prostate cancer cells.
AID220971putrescine Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID169975Compound was evaluated for agonist activity at 10 uM exhibiting moderate antagonism of [3H]MK-801 binding relative to 100% control1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Impact of polyamine analogues on the NMDA receptor.
AID99099Compound was evaluated for its impact on putrescine (Put) levels after 48 hr at concentration 10 uM1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Antiproliferative properties of polyamine analogues: a structure-activity study.
AID99137Compound was evaluated for its impact on spermine levels after 48 hr at concentration 10 uM1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Antiproliferative properties of polyamine analogues: a structure-activity study.
AID220972putrescine Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID98319Growth uM after 48 hours2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID220839MESPM/MEHSPH Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID96885Spermine(SPM) levels in L1210 cells after 48 hr of treatment with the compound at the dose of 0.75 uM2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID220833Distribution in liver was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-36 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID169976Compound was evaluated for agonist activity at 1 uM exhibiting moderate antagonism of [3H]MK-801 binding relative to 100% control1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Impact of polyamine analogues on the NMDA receptor.
AID26648Acid base constant value for N2 atom1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study.
AID220962putrescine Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID220830Distribution in liver was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-27 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID98380In vitro inhibition of L1210 growth after 96 hours.1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Antiproliferative properties of polyamine analogues: a structure-activity study.
AID44519The acute toxicity was determined in female CD1 mice after (ip) administration2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID94585Inhibitory activity against growth of JURKAT cells after 144h.1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID218604Spermidine Distribution in liver was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-22 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
AID96743Putrescine(PUT) levels in L1210 cells after 48 hr of treatment with the compound at the dose of 10 uM2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID96884Spermine(SPM) levels in L1210 cells after 48 hr of treatment with the compound at the dose of 0.15 uM2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
AID98648Effect of compound on polyamine biosynthetic enzymes in L1210 cells using ODC assay1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Effect of polyamine analogues on hypusine content in JURKAT T-cells.
AID220981putrescine putrescine Distribution in kidney was determined after DEHSPM dosing of 2.0 mg/kg/day for 29 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-58 mg/kg)2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Polyamine analogue antidiarrheals: a structure-activity study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.90)18.7374
1990's20 (68.97)18.2507
2000's7 (24.14)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.93 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index5.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.45%)5.53%
Reviews2 (6.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (89.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
putrescine
[no description available]		2.6730alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
spermidine
[no description available]		3.0850polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
spermine
[no description available]		5.9241polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		2.3820alpha-amino acid;
fluoroamino acid		trypanocidal drug
entinostat
[no description available]		3.1410benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
n(1),n(11)-diethylnorspermine
N(1),N(11)-diethylnorspermine: structure given in first source		5.54130
n(1), n(12)-diethylspermine
N(1), N(12)-diethylspermine: structure in first source. N(1),N(12)-diethylspermine : A substituted spermine that is spermine in which a hydrogen attached to each of the primary amino groups has been replaced by an ethyl group.		5.3100polyazaalkane;
secondary amino compound;
substituted spermine;
tetramine		antineoplastic agent
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		3.1410dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		1.9910aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
melarsen oxide
melarsen oxide: inhibits glutathione reductase		3.110
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		1.9910pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
hypusine
hypusine: N-terminal amino alcohol deriv of Lys occurring in bovine brain & in the urine of children with familial hyperlysinemia; minor descriptor (75-82); online & Index Medicus search LYSINE/AA (75-82). hypusine : An L-lysine derivative that is L-lysine bearing a (2R)-4-amino-2-hydroxybutyl substituent at position N(6).		1.9910
mdl 27695
MDL 27695: structure given in first source		4.0420
norspermine
3,3,3-tetramine : A polyazaalkane consisting of a 13-membered straight chain alkane with aza-groups at the 1-, 5-, 9- and 13-positions.		1.9910polyazaalkane;
tetramine
s-adenosyl-3-thio-1,8-diaminooctane
S-adenosyl-3-thio-1,8-diaminooctane: structure given in first source		3.110
deoxyhypusine
deoxyhypusine : An L-lysine derivative in which the N(6) of the lysine is substituted with a 4-aminobutyl group.		1.9910L-lysine derivative;
non-proteinogenic L-alpha-amino acid		human metabolite
n(1),n(8)-diethylspermidine
N(1),N(8)-diethylspermidine: regulator of ornithine decarboxylase		3.4920
be 4-4-4-4
BE 4-4-4-4: structure given in first source		3.5120
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		3.1410antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
s-adenosyl-1,12-diamino-3-thio-9-azadodecane
S-adenosyl-1,12-diamino-3-thio-9-azadodecane: structure given in first source		3.110
mitoguazone
Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.		3.110guanidines;
hydrazone		antineoplastic agent;
apoptosis inducer;
EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
cgc 11047
CGC 11047: may prove useful in promoting regression of choroidal neovascularization		3.1410
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		03.0850
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		14.420
Opportunistic Infections
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.		02.9210
Cancer of Prostate
[description not available]		0210
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		0210
Breast Cancer
[description not available]		02.9610
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.9610
Cholera Infantum
[description not available]		03.411
Benign Neoplasms
[description not available]		03.411
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.411
Benign Neoplasms, Brain
[description not available]		03.0850
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		03.0850
Bladder Cancer
[description not available]		01.9810
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		01.9810
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.		01.9810
Blood Pressure, High
[description not available]		01.9810
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		01.9810
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		01.9910
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		01.9910
Colonic Diseases, Functional
Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.		0210
Malignant Melanoma
[description not available]		01.9810
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		01.9810
Adenocarcinoma, Basal Cell
[description not available]		02.3820
Cancer of Pancreas
[description not available]		02.3820
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.3820
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.3820
Carcinoma, Oat Cell
[description not available]		01.9710
Carcinoma, Anaplastic
[description not available]		01.9710
Cancer of Lung
[description not available]		01.9710
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		01.9710
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9710
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		01.9710